Icariside II inhibits lipopolysaccharide-induced inflammation and amyloid production in rat astrocytes by regulating IKK/IκB/NF-κB/BACE1 signaling pathway
- 25 September 2019
- journal article
- research article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 41 (2) , 154-162
Abstract
β-amyloid (Aβ) is one of the inducing factors of astrocytes activation and neuroinflammation, and it is also a crucial factor for the development of Alzheimer’s disease (AD). Icariside II (ICS II) is an active component isolated from a traditional Chinese herb Epimedium, which has shown to attnuate lipopolysaccharide (LPS)-induced neuroinflammation through regulation of NF-κB signaling pathway. In this study we investigated the effects of ICS II on LPS-induced astrocytes activation and Aβ accumulation. Primary rat astrocytes were pretreated with ICS II (5, 10, and 20 μM) or dexamethasone (DXMS, 1 μM) for 1 h, thereafter, treated with LPS for another 24 h. We found that ICS II pretreatment dose dependently mitigated the levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) in the astrocytes. Moreover, ICS II not only exerted the inhibitory effect on LPS-induced IκB-α degradation and NF-κB activation, but also decreased the levels of Aβ1–40, Aβ1–42, amyloid precursor protein (APP) and beta secretase 1 (BACE1) in the astrocytes. Interestingly, molecular docking revealed that ICS II might directly bind to BACE1. It is concluded that ICS II has potential value as a new therapeutic agent to treat neuroinflammation-related diseases, such as AD.Keywords
This publication has 59 references indexed in Scilit:
- Large-scale production of soluble recombinant amyloid-β peptide 1–42 using cold-inducible expression systemProtein Expression and Purification, 2012
- A Review: Inflammatory Process in Alzheimer's Disease, Role of CytokinesThe Scientific World Journal, 2012
- The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesisJournal of Neuroinflammation, 2011
- Effects of non‐steroidal anti‐inflammatory drug treatments on cognitive decline vary by phase of pre‐clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti‐inflammatory Prevention TrialInternational Journal of Geriatric Psychiatry, 2011
- Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's diseaseInternational Journal of Neuropsychopharmacology, 2011
- Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generationJournal of Neuroinflammation, 2008
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- In Vivo β-Secretase 1 Inhibition Leads to Brain Aβ Lowering and Increased α-Secretase Processing of Amyloid Precursor Protein without Effect on Neuregulin-1The Journal of Pharmacology and Experimental Therapeutics, 2008
- LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropeniaNature Medicine, 2006
- Gene structure and organization of the human β‐secretase ( BACE ) promoterThe FASEB Journal, 2004